Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Joshua E ReussValsamo AnagnostouTricia R CottrellKellie N SmithFranco VerdeMarianna ZahurakMara LanisJoseph C MurrayHok Yee ChanCaroline McCarthyDaphne WangJames R WhiteStephen YangRichard BattafaranoStephen BroderickErrol BushMalcolm BrockJinny HaDavid JonesTaha MerghoubJanis TaubeVictor E VelculescuGary RosnerPeter IlleiDrew M PardollSuzanne TopalianJarushka NaidooBen LevyMatthew HellmannJulie R BrahmerJamie E ChaftPatrick M FordePublished in: Journal for immunotherapy of cancer (2021)
Though treatment was feasible, due to toxicity the study arm was terminated early by investigator consensus. In light of this, and while the long-term disease-free status of patients who achieved pCR is encouraging, further investigation of neoadjuvant nivolumab plus ipilimumab in patients with resectable NSCLC requires the identification of predictive biomarkers that enrich for response.